Genaissance Pharmaceuticals Comments on Stock Activity

Genaissance Pharmaceuticals Comments on Stock Activity 


NEW HAVEN, Conn., April 28  /PRNewswire-FirstCall/ -- Genaissance
Pharmaceuticals, Inc. (NASDAQ:GNSC) today commented that nothing fundamental in
the Company's operations has changed to cause the current market activity in
its Common Stock.

As a reminder, Genaissance will host a conference call on Tuesday, May 3, 2005,
at 11:00 a.m. Eastern time in conjunction with the release of its financial
results for the first quarter ended March 31, 2005.

Genaissance will be presenting at the Rodman & Renshaw Techvest 2nd Annual
Global Healthcare Conference in Paris, France, at 3:30 p.m. local time (9:30
a.m. Eastern time) on Wednesday, May 4, 2005.

Genaissance Pharmaceuticals, Inc. is developing innovative products based on
its proprietary pharmacogenomic technology and has a revenue-generating
business in DNA and pharmacogenomic products and services.  Genaissance also
markets its proprietary FAMILION(TM) Test, designed to detect mutations
responsible for causing Familial Long QT and Brugada Syndromes, two causes of
sudden cardiac death.  The Company's product development strategy is focused on
drug candidates with promising clinical profiles and finding genetic markers to
identify a responsive patient population.  This strategy is designed to enable
Genaissance to leverage existing clinical data and, thus, reduce the costs and
risks associated with traditional drug development and increase the probability
of clinical success and commercialization.  The Company's lead therapeutic
product, vilazodone for depression, is in Phase II of development.  For more
information on Genaissance, visit the Company's website at:
http://www.genaissance.com/. 

DATASOURCE: Genaissance Pharmaceuticals, Inc.



CONTACT:  Kevin Rakin, President & Chief Executive Officer, Genaissance

Pharmaceuticals, Inc., [phone]; or Rhonda Chiger (investors), Rx

Communications Group, [phone]; or Tom Redington (media), Redington,

Inc., [phone], for Genaissance Pharmaceuticals



Web site:  http://www.genaissance.com/ 

Copyright